Detalles de la búsqueda
1.
2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial.
Acta Oncol
; 61(8): 963-971, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35847998
2.
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Lancet Oncol
; 22(2): 235-245, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33444529
3.
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Lancet
; 394(10196): 385-395, 2019 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31227373
4.
Effects of a nutrition intervention on acute and late bowel symptoms and health-related quality of life up to 24 months post radiotherapy in patients with prostate cancer: a multicentre randomised controlled trial.
Support Care Cancer
; 28(7): 3331-3342, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31758324
5.
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
Lancet Oncol
; 14(2): 117-24, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23294853
6.
Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study.
Anticancer Res
; 42(1): 87-92, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34969712
7.
Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.
Eur Urol
; 76(6): 823-830, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31443961
8.
Adipose tissue concentrations of persistent organic pollutants and the risk of prostate cancer.
J Occup Environ Med
; 48(7): 700-7, 2006 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-16832227
9.
Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study.
J Pain Symptom Manage
; 29(4): 352-7, 2005 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15857738
10.
Corrigendum re "Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial" [Eur Urol 2019;76:823-30].
Eur Urol
; 78(6): e241-e242, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32893063
11.
Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer.
Anticancer Res
; 32(3): 953-6, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22399616
12.
Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.
Eur Urol
; 52(6): 1691-8, 2007 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17306441
Resultados
1 -
12
de 12
1
Próxima >
>>